Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Substance Withdrawal Syndrome 1Prostatic Neoplasms 1Melanoma 1Kidney Neoplasms 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 3Mastectomy, Segmental 2Immunohistochemistry 2talimogene laherparepvec 1abemaciclib 1Surgical Procedures, Operative 1Sugars 1Specimen Handling 1Radiotherapy 1Radiation 1Nivolumab 1Naltrexone 1Mass Spectrometry 1Lovastatin 1Ipilimumab 1Infliximab 1Hypericum extract LI 160 1Genotype 1Gels 1Gefitinib 1Fluorescent Antibody Technique 1Flow Cytometry 1Chromatography, Liquid 1Chemotherapy, Adjuvant 1Celecoxib 1CTLA-4 Antigen 1Brachytherapy 1Biopsy, Needle 1Biopsy, Fine-Needle 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Carcinoma In Situ × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡